SCOLR May File NDA For Ibuprofen Product Following Break With Wyeth
This article was originally published in The Tan Sheet
Executive Summary
SCOLR Pharma will either file an NDA with FDA or work with another pharmaceutical company to develop its 12-hour extended-release ibuprofen product after Wyeth announced it will terminate an agreement with the firm effective April 16
You may also be interested in...
SCOLR Ready To Answer FDA Questions On 12-Hour Pseudoephedrine ANDA
FDA has raised questions on "minor" issues regarding SCOLR Pharma's proposed nonprescription 12-hour pseudoephedrine tablet, according to the firm
SCOLR’s sales drop
Revenues for the first quarter declined 76 percent to $265,555 for Bellevue, Wash.-based SCOLR Pharma, the firm announces May 2. The firm credits the previous year's higher revenues during the January-March period to $795,000 of research and development fees and licensing revenues from a terminated license agreement. Wyeth terminated a licensing agreement to use SCOLR's controlled delivery technology in OTC formulations (1"The Tan Sheet" March 19, 2007, p. 13). However, SCOLR is optimistic about its development of ibuprofen and pseudoephedrine formulas, its "lead product candidates." The firm this year announced the completion of two drug trials and plans for a 12-hour release of an OTC ibuprofen product (2"The Tan Sheet" March 24, 2008, In Brief)...
SCOLR Expects New Licensing Agreement This Year
SCOLR Pharma says it could have a new licensing agreement for an extended release ibuprofen product made with its patented Controlled Delivery Technology by September of this year